Cambridge, UK (November 2, 2020) — BioStrata, a specialist life science marketing and PR agency, has appointed a new senior team member to support continued and significant client growth in the United States. Jessica Grant, a B2B communications specialist with over 16 years’ experience, joins BioStrata as an Account Director based in Portland, Oregon, further building the company’s established global footprint.
News
Leaders in stem cell research and cell therapy to help drive development of scalable off-the-shelf therapies for diseases with a high unmet clinical need
WALTHAM, Mass.--(BUSINESS WIRE
RaDaR ctDNA liquid biopsy test to be used to monitor patient response in Phase 1/2 study of MVC-101 in multiple tumor types
Research Triangle Park, NC, USA and Cambridge, UK, 29 October 2020 – Inivata, a leader in liquid biopsy, today announces a collaboration with Maverick Therapeutics (“Maverick”) for the use of Inivata’s RaDaR™ assay for the detection and monitoring of residual disease and recurrence. RaDaR will be used to monitor circulating tumor DNA (ctDNA) in patients enrolled in the Phase 1/2 study of MVC-101, Maverick’s lead program candidate.
• Announcing the challenge
This week the 7th CSP Blind Test begins - a major challenge in computational chemistry. It will see the world leading methods in Crystal Structure Prediction put to the test on real targets - with a high bar set by previous work. The 7 test systems have been sourced from leading experimentalists in industry and academia for prediction.
• The importance of CSP
The 3D structure and packing of crystalline materials have a big impact on their properties - this is most relevant in drug discovery and development.
The DimAb™ development platform is different from traditional hybridoma fusion technologies in that it can directly isolate IgG genes from B cells of immunized animals. Using this novel platform - a number of custom development projects have already been completed with high customer satisfaction.
London and Cambridge, October 20, 2020 - Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc. The agreement builds on Hikma and Arecor’s first product co-development agreement, which was announced on 9 January 2020.
Westbury, NY – Oct. 19, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today launched its HEPATOMUNE® kit, a long-term, stable, in vitro model for evaluating immune-related and inflammation-mediated liver injury.
AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of SARS-CoV-2 antibodies and antigens to aid development of new immunoassay diagnostic kits.